<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2309">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131100</url>
  </required_header>
  <id_info>
    <org_study_id>A6291047</org_study_id>
    <nct_id>NCT05131100</nct_id>
  </id_info>
  <brief_title>Korean Regulatory Post Marketing Surveillance for Somavert</brief_title>
  <official_title>Korean Post-marketing Surveillance for Somavert</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Non-interventional observational study, to identify safety and effectiveness of Somavert&#xD;
      during the post-marketing period based on the Korean RMP as required by the regulations of&#xD;
      Ministry of Food and Drug Safety (MFDS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">February 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experience adverse events</measure>
    <time_frame>Baseline through 28 days after last dose (approximately 52 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience Clinical Improvement as assessed by investigator</measure>
    <time_frame>Baseline through approximately 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Participants receiving Somavert</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somavert</intervention_name>
    <description>As provided in real world practice</description>
    <arm_group_label>Participants receiving Somavert</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult acromegaly patients who have had an inadequate response to surgery and/or radiation&#xD;
        therapy and in whom appropriate medical treatment with somatostatin analogues did not&#xD;
        normalize IGF-1 concentrations or was not tolerated&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients who have been prescribed as per local label and investigators' judgement under&#xD;
        the setting of routine practice in Korea who are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who are contraindicated for Somavert&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acromegaly, Somavert, Post-Marketing Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

